SCHEMBL1237684

SCHEMBL1237684

CCCCCCCCCCCCNC(=O)C1(C)C[C@](C)(C(=O)NCCCCCCCCCCCC)C[C@@](C)(C(=O)NCCCCCCCCCCCC)C1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
LMNA P02545 1/20 0.56
EPHX1 P07099 7/20 0.55
NPSR1 Q6W5P4 1/20 0.55
SPHK1 Q9NYA1 6/20 0.53
CASP2 P42575 1/20 0.50
CYP3A4 P08684 1/20 0.48
CYP2C19 P33261 1/20 0.48
NAAA Q02083 2/20 0.47
ZDHHC20 Q5W0Z9 1/20 0.47
ZDHHC2 Q9UIJ5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1236881 1.00 HPGD (0.56) HPGDSMN1; SMN2LMNAEPHX1NPSR1
SCHEMBL1237682 1.00 HPGD (0.56) HPGDSMN1; SMN2LMNAEPHX1NPSR1
SCHEMBL1236882 1.00 HPGD (0.56) HPGDSMN1; SMN2LMNAEPHX1NPSR1
SCHEMBL5408092 0.90 EPHX2 (0.54)
SCHEMBL30100538 0.90 HPGD (0.47) HPGDSMN1; SMN2LMNAEPHX1NPSR1
SCHEMBL5408085 0.90 EPHX2 (0.54)
SCHEMBL5413708 0.90 EPHX2 (0.54)
SCHEMBL5413720 0.90 EPHX2 (0.54)
SCHEMBL5413712 0.90 EPHX2 (0.54)
SCHEMBL30100510 0.87 HPGD (0.44) HPGDSMN1; SMN2LMNAEPHX1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820146-B2 Care and/or make-up cosmetic composition structured with silicone polymers and organogelling agents, in rigid form L'OREAL S.A. (FR) 2010-10-26 US claimed
US-20050245673-A1 Care and/or make-up cosmetic composition structured with silicone polymers and organogelling agents, in rigid form L'OREAL S.A. (FR) 2005-11-03 US claimed
US-20040223987-A1 Composition structured with a polymer containing a heteroatom and organogelator L'OREAL S.A. (FR) 2004-11-11 US claimed
EP-1068854-B1 Solid form composition comprising an oil and a specific gelling agent, process for cosmetic treatment and use of this compound OREAL (FR) 2004-08-18 EP claimed
WO-2002047628-A1 COMPOSITION STRUCTURED WITH A POLYMER CONTAINING A HETEROATOM AND AN ORGANOGELATOR L'ORÉAL (FR) 2002-06-20 WO claimed
US-6372235-B1 Compositions in solid form comprising an oil and a specific gelling compound, cosmetic treatment processes, and use of the compound L'OREAL, S.A. (FR) 2002-04-16 US claimed
EP-1068854-A1 Solid form composition comprising an oil and a specific gelling agent, process for cosmetic treatment and use of this compound L'OREAL (FR) 2001-01-17 EP claimed
EP-1676556-B1 Cosmetic composition containing a polyorganosiloxane polymer OREAL (FR) 2012-01-11 EP disclosed
US-20110189117-A1 COSMETIC COMPOSITION CONTAINING A POLYORGANISILOXANE POLYMER L'OREAL (FR) 2011-08-04 US disclosed
US-7879316-B2 Mixture of polyamide-siloxane copolymer in volatile oil; cosmetics L'OREAL (FR) 2011-02-01 US disclosed
US-7820146-B2 Care and/or make-up cosmetic composition structured with silicone polymers and organogelling agents, in rigid form L'OREAL S.A. (FR) 2010-10-26 US disclosed
US-7803356-B2 Compositions containing at least one silicone resin and a volatile non-cyclic silicone oil L'OREAL (FR) 2010-09-28 US disclosed
US-7758848-B2 Cosmetic composition containing a polyorganosiloxane polymer L'OREAL (FR) 2010-07-20 US disclosed
US-20040170586-A1 Cosmetic composition containing a polyorganosiloxane polymer L'OREAL (FR) 2004-09-02 US disclosed
EP-1068854-B1 Solid form composition comprising an oil and a specific gelling agent, process for cosmetic treatment and use of this compound OREAL (FR) 2004-08-18 EP disclosed
US-20030091520-A1 Use of at least one polar additive in a cosmetic composition comprising a liquid fatty phase structured by at least one molecular organogelator, to impart a thixotropic character to the composition L'OREAL (FR) 2003-05-15 US disclosed
EP-1264589-A1 Use of a polar additive in a cosmetic composition containing a structured liquid oil phase by at least one organogelator to give a thixotropic character L'OREAL (FR) 2002-12-11 EP disclosed
WO-2002047628-A1 COMPOSITION STRUCTURED WITH A POLYMER CONTAINING A HETEROATOM AND AN ORGANOGELATOR L'ORÉAL (FR) 2002-06-20 WO disclosed
US-6372235-B1 Compositions in solid form comprising an oil and a specific gelling compound, cosmetic treatment processes, and use of the compound L'OREAL, S.A. (FR) 2002-04-16 US disclosed
EP-1068854-A1 Solid form composition comprising an oil and a specific gelling agent, process for cosmetic treatment and use of this compound L'OREAL (FR) 2001-01-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040223987-A1 Composition structured with a polymer containing a heteroatom and organogelator CUTA, PARG, FABP4 HPGD 471/4885SMN1; SMN2 3493/4885LMNA 1848/4885
US-20040170586-A1 Cosmetic composition containing a polyorganosiloxane polymer CUTA, XPA, PRDX1 HPGD 312/4885SMN1; SMN2 2953/4885LMNA 3883/4885
US-20110189117-A1 COSMETIC COMPOSITION CONTAINING A POLYORGANISILOXANE POLYMER CUTA, PRDX1, PRXL2A HPGD 504/4885SMN1; SMN2 1956/4885LMNA 4087/4885
US-20030091520-A1 Use of at least one polar additive in a cosmetic composition comprising a liquid fatty phase structured by at least one molecular organogelator, to impart a thixotropic character to the composition PLIN3, CUTA, FABP4 HPGD 2166/4885SMN1; SMN2 4783/4885LMNA 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.